Marksans Pharma Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Strong return on equity (ROE 15.2%)
- ✓Efficient capital deployment (ROCE 18.8%)
- ✓Attractively valued vs sector (P/E 29x vs industry 54.4x)
- ✓Low debt relative to equity (D/E 0.1x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MARKSANS · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.85% | 43.85% | 43.87% | 43.87% | 43.87% | 43.87% |
| FII | 15.55% | 15.57% | 18.59% | 21.31% | 21.95% | 22.19% |
| DII | 4.76% | 5.17% | 3.75% | 4.10% | 4.30% | 4.55% |
| Public | 35.81% | 35.40% | 33.77% | 30.70% | 29.88% | 29.37% |
Corporate Events
To consider and approve Audited Standalone and Consolidated Financial Results and to consider recommendation of dividend if any, for the Financial Year ended March 31, 2026
Dividend - Re 0.80 Per Share
Dividend - Rs 0.60 Per Share
Dividend - Re 0.50 Per Share
Latest News
All news →Marksans Pharma to acquire German firm ABCnow GmbH
*Marksans Pharma to acquire German firm ABCnow GmbH* — Marksans Pharma has signed a definitive agreement to acquire 100% of Germany-based ABCnow GmbH. The acquisition marks a strategic step in expanding its global footprint. Details of the deal size and financial impact were not disclosed. \n\n📊 *STOCKS:* MARKSANS | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
Marksans Pharma announces board meeting outcome.
*Marksans Pharma announces outcome of board meeting.* The meeting held on July 03, 2026, discussed routine matters including financial disclosures and corporate proposals. No major strategic announcements or financial surprises were revealed. Details are available in the official NSE filing. 📊 *STOCKS:* MARKSANS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Marksans Pharma to expand generic drug portfolio in US.
*Marksans Pharma to expand generic drug portfolio in US.* The company highlighted growth plans during an analyst and institutional investor meet. Focus remains on scaling US market presence with **~$50 million** in potential revenue from new filings. Regulatory submissions expected to drive future earnings. 📊 *STOCKS:* $MARKSANSPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Marksans Pharma to pay dividend, record date set
*Marksans Pharma to pay dividend, record date set*\nMarksans Pharma has announced a dividend with a record date of **20 August 2026**. The payment will follow after this date. Shareholders as of the record date are eligible.\n\n📊 *STOCKS:* MARKSANS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Marksans Pharma issues general corporate updates
*Marksans Pharma issues general corporate updates.* No specific financial figures or strategic announcements disclosed in the filing. The update appears to be routine in nature. Traders should monitor for further clarity. 📊 *STOCKS:* MARKSANS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
Marksans Pharma sets dividend record date
*Marksans Pharma sets dividend record date.* The company has set **20-Aug-2026** as the record date for dividend distribution. This is a routine corporate action with no surprise element. Retail traders may see minor movement ahead of the date. 📊 *STOCKS:* MARKSANS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Marksans Pharma sets dividend record date
*Marksans Pharma sets dividend record date* Marksans Pharma Limited has announced **20-Aug-2026** as the record date for dividend distribution. Shareholders registered on or before this date will be eligible for the payout. The quantum and declaration date of the dividend are yet to be disclosed. 📊 *STOCKS:* MARKSANS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Marksans Pharma announces updates related to QliniQ B.V.
*Marksans Pharma announces general updates related to QliniQ B.V.* The filing provides corporate updates involving its subsidiary, QliniQ B.V., though specific financial or strategic details are not disclosed. No immediate material impact is evident from the announcement. Further clarity may emerge upon detailed disclosures. 📊 *STOCKS:* MARKSANS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateUpdate
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹754 Cr ▲4.7% | ₹720 Cr ▲16.1% | ₹620 Cr ▼12.4% | ₹708 Cr ▲3.8% | ₹682 Cr ▲6.2% | ₹642 Cr ▲8.6% | ₹591 Cr ▲5.5% | ₹560 Cr |
| Op. Profit | ₹161 Cr ▲11.8% | ₹144 Cr ▲44.0% | ₹100 Cr ▼21.3% | ₹127 Cr ▼8.6% | ₹139 Cr ▼5.4% | ₹147 Cr ▲14.8% | ₹128 Cr ▲16.4% | ₹110 Cr |
| OPM | 21.0% ▲5.0% | 20.0% ▲25.0% | 16.0% ▼11.1% | 18.0% ▼10.0% | 20.0% ▼13.0% | 23.0% ▲4.5% | 22.0% ▲10.0% | 20.0% |
| Net Profit | ₹114 Cr ▲15.2% | ₹99 Cr ▲70.7% | ₹58 Cr ▼36.3% | ₹91 Cr ▼13.3% | ₹105 Cr ▲7.1% | ₹98 Cr ▲10.1% | ₹89 Cr ▲14.1% | ₹78 Cr |
| EPS (₹) | 2.5 ▲15.2% | 2.17 ▲68.2% | 1.29 ▼35.5% | 2 ▼13.4% | 2.31 ▲8.5% | 2.13 ▲8.7% | 1.96 ▲13.3% | 1.73 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.0K Cr ▲12.5% | ₹2.6K Cr ▲20.5% | ₹2.2K Cr ▲17.5% | ₹1.9K Cr ▲24.2% | ₹1.5K Cr ▲8.4% | ₹1.4K Cr ▲21.3% | ₹1.1K Cr ▲13.4% | ₹1.0K Cr ▲9.5% | ₹913 Cr ▲19.0% | ₹767 Cr |
| Expenses | ₹2.4K Cr ▲12.2% | ₹2.1K Cr ▲21.8% | ₹1.7K Cr ▲13.6% | ₹1.5K Cr ▲22.8% | ₹1.2K Cr ▲18.8% | ₹1.0K Cr ▲10.1% | ₹942 Cr ▲8.5% | ₹868 Cr ▲4.1% | ₹834 Cr ▲15.5% | ₹722 Cr |
| Op. Profit | ₹601 Cr ▲13.6% | ₹529 Cr ▲15.3% | ₹459 Cr ▲35.0% | ₹340 Cr ▲31.3% | ₹259 Cr ▼23.8% | ₹340 Cr ▲77.1% | ₹192 Cr ▲45.5% | ₹132 Cr ▲69.2% | ₹78 Cr ▲73.3% | ₹45 Cr |
| OPM | 20.0% ▲0.0% | 20.0% ▼4.8% | 21.0% ▲16.7% | 18.0% ▲5.9% | 17.0% ▼32.0% | 25.0% ▲47.1% | 17.0% ▲30.8% | 13.0% ▲44.4% | 9.0% ▲50.0% | 6.0% |
| Other Income | ₹83 Cr ▲18.6% | ₹70 Cr ▲40.0% | ₹50 Cr ▼15.3% | ₹59 Cr ▲40.5% | ₹42 Cr ▲500.0% | ₹7 Cr | ₹0 Cr ▼100.0% | ₹5 Cr ▼37.5% | ₹8 Cr ▲14.3% | ₹7 Cr |
| Interest | ₹24 Cr ▲100.0% | ₹12 Cr ▲9.1% | ₹11 Cr ▲22.2% | ₹9 Cr ▲12.5% | ₹8 Cr ▲0.0% | ₹8 Cr ▼11.1% | ₹9 Cr ▼10.0% | ₹10 Cr ▲0.0% | ₹10 Cr ▲42.9% | ₹7 Cr |
| Depreciation | ₹99 Cr ▲19.3% | ₹83 Cr ▲12.2% | ₹74 Cr ▲42.3% | ₹52 Cr ▲15.6% | ₹45 Cr ▲25.0% | ₹36 Cr ▲33.3% | ₹27 Cr ▲17.4% | ₹23 Cr ▼14.8% | ₹27 Cr ▼10.0% | ₹30 Cr |
| PBT | ₹561 Cr ▲11.3% | ₹504 Cr ▲18.9% | ₹424 Cr ▲25.4% | ₹338 Cr ▲36.3% | ₹248 Cr ▼17.9% | ₹302 Cr ▲92.4% | ₹157 Cr ▲51.0% | ₹104 Cr ▲108.0% | ₹50 Cr ▲233.3% | ₹15 Cr |
| Tax % | 25.0% ▲4.2% | 24.0% ▼7.7% | 26.0% ▲23.8% | 21.0% ▼16.0% | 25.0% ▲19.0% | 21.0% ▼8.7% | 23.0% ▲0.0% | 23.0% ▼17.9% | 28.0% ▲16.7% | 24.0% |
| Net Profit | ₹420 Cr ▲9.7% | ₹383 Cr ▲21.6% | ₹315 Cr ▲18.9% | ₹265 Cr ▲41.7% | ₹187 Cr ▼21.8% | ₹239 Cr ▲97.5% | ₹121 Cr ▲51.2% | ₹80 Cr ▲122.2% | ₹36 Cr ▲227.3% | ₹11 Cr |
| EPS (₹) | 9.22 ▲9.8% | 8.4 ▲21.4% | 6.92 ▲17.7% | 5.88 ▲30.4% | 4.51 ▼21.7% | 5.76 ▲95.3% | 2.95 ▲57.8% | 1.87 ▲133.8% | 0.8 ▲263.6% | 0.22 |
| Div Payout | 10.0% ▲0.0% | 10.0% ▲11.1% | 9.0% ▲0.0% | 9.0% ▲50.0% | 6.0% ▲50.0% | 4.0% ▲33.3% | 3.0% ▲0.0% | 3.0% ▼50.0% | 6.0% ▼73.9% | 23.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹45 Cr ▲0.0% | ₹45 Cr ▲0.0% | ₹45 Cr ▲0.0% | ₹45 Cr ▲9.8% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr |
| Reserves | ₹2.6K Cr ▲9.1% | ₹2.4K Cr ▲19.9% | ₹2.0K Cr ▲18.8% | ₹1.7K Cr ▲46.4% | ₹1.2K Cr ▲37.2% | ₹846 Cr ▲42.2% | ₹595 Cr ▲18.5% | ₹502 Cr ▲16.7% | ₹430 Cr ▲9.7% | ₹392 Cr |
| Borrowings | ₹332 Cr ▲3.1% | ₹322 Cr ▲32.0% | ₹244 Cr ▲98.4% | ₹123 Cr ▲10.8% | ₹111 Cr ▲226.5% | ₹34 Cr ▲13.3% | ₹30 Cr ▼70.0% | ₹100 Cr ▼15.3% | ₹118 Cr ▲7.3% | ₹110 Cr |
| Other Liabilities | ₹422 Cr ▼6.4% | ₹451 Cr ▲21.2% | ₹372 Cr ▲15.5% | ₹322 Cr ▼0.3% | ₹323 Cr ▲5.2% | ₹307 Cr ▲30.1% | ₹236 Cr ▲47.5% | ₹160 Cr ▲12.7% | ₹142 Cr ▼32.1% | ₹209 Cr |
| Total Liabilities | ₹3.4K Cr ▲6.2% | ₹3.2K Cr ▲20.9% | ₹2.7K Cr ▲22.4% | ₹2.2K Cr ▲33.9% | ₹1.6K Cr ▲33.2% | ₹1.2K Cr ▲36.1% | ₹902 Cr ▲12.5% | ₹802 Cr ▲9.7% | ₹731 Cr ▼2.8% | ₹752 Cr |
| Assets | ||||||||||
| Fixed Assets | ₹1.1K Cr ▲7.3% | ₹982 Cr ▲26.5% | ₹776 Cr ▲59.7% | ₹486 Cr ▲13.6% | ₹428 Cr ▲38.5% | ₹309 Cr ▲2.0% | ₹303 Cr ▲12.2% | ₹270 Cr ▼3.2% | ₹279 Cr ▲4.5% | ₹267 Cr |
| CWIP | ₹7 Cr ▼74.1% | ₹27 Cr ▲200.0% | ₹9 Cr ▼10.0% | ₹10 Cr ▲233.3% | ₹3 Cr ▼75.0% | ₹12 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹1 Cr ▲0.0% | ₹1 Cr ▼96.3% | ₹27 Cr ▲2600.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹2.4K Cr ▲6.8% | ₹2.2K Cr ▲19.3% | ₹1.9K Cr ▲10.3% | ₹1.7K Cr ▲40.6% | ₹1.2K Cr ▲32.9% | ₹907 Cr ▲51.4% | ₹599 Cr ▲12.4% | ₹533 Cr ▲18.2% | ₹451 Cr ▼6.8% | ₹484 Cr |
| Total Assets | ₹3.4K Cr ▲6.2% | ₹3.2K Cr ▲20.9% | ₹2.7K Cr ▲22.4% | ₹2.2K Cr ▲33.9% | ₹1.6K Cr ▲33.2% | ₹1.2K Cr ▲36.1% | ₹902 Cr ▲12.5% | ₹802 Cr ▲9.7% | ₹731 Cr ▼2.8% | ₹752 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹207 Cr ▼10.0% | ₹230 Cr ▼3.0% | ₹237 Cr ▲139.4% | ₹99 Cr ▼44.7% | ₹179 Cr ▼23.2% | ₹233 Cr ▲763.0% | ₹27 Cr ▼46.0% | ₹50 Cr ▲257.1% | ₹14 Cr ▼54.8% | ₹31 Cr |
| Investing CF | ₹-49 Cr ▲65.2% | ₹-141 Cr ▲45.6% | ₹-259 Cr ▼208.3% | ₹-84 Cr ▼86.7% | ₹-45 Cr ▲25.0% | ₹-60 Cr ▼361.5% | ₹-13 Cr ▲66.7% | ₹-39 Cr ▼85.7% | ₹-21 Cr ▲82.9% | ₹-123 Cr |
| Financing CF | ₹-65 Cr ▲5.8% | ₹-69 Cr ▼134.8% | ₹198 Cr ▲147.5% | ₹80 Cr ▲633.3% | ₹-15 Cr ▲86.8% | ₹-114 Cr ▼442.9% | ₹-21 Cr ▼800.0% | ₹3 Cr ▲200.0% | ₹-3 Cr ▲94.8% | ₹-58 Cr |
| Net Cash Flow | ₹93 Cr ▲342.9% | ₹21 Cr ▼88.1% | ₹176 Cr ▲87.2% | ₹94 Cr ▼20.3% | ₹118 Cr ▲96.7% | ₹60 Cr ▲957.1% | ₹-7 Cr ▼146.7% | ₹15 Cr ▲250.0% | ₹-10 Cr ▲93.3% | ₹-150 Cr |
| Free Cash Flow | ₹35 Cr ▲59.1% | ₹22 Cr ▼88.0% | ₹184 Cr ▲247.2% | ₹53 Cr ▼60.2% | ₹133 Cr ▼23.6% | ₹174 Cr ▲1142.9% | ₹14 Cr ▲27.3% | ₹11 Cr ▲178.6% | ₹-14 Cr ▲86.1% | ₹-101 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75d ▼1.3% | 76d ▼7.3% | 82d ▼15.5% | 97d ▲34.7% | 72d ▼7.7% | 78d ▲21.9% | 64d ▼9.9% | 71d ▼39.8% | 118d ▲32.6% | 89d |
| Inventory Days | 270d ▲24.4% | 217d ▲13.0% | 192d ▼11.1% | 216d ▼12.9% | 248d ▲60.0% | 155d ▼27.9% | 215d ▲41.4% | 152d ▲0.7% | 151d ▲25.8% | 120d |
| Days Payable | 98d ▲4.3% | 94d ▲3.3% | 91d ▼10.8% | 102d ▼1.0% | 103d ▲45.1% | 71d ▼9.0% | 78d ▲44.4% | 54d ▼58.1% | 129d ▲51.8% | 85d |
| Cash Conv. Cycle | 247d ▲24.1% | 199d ▲8.7% | 183d ▼13.3% | 211d ▼2.8% | 217d ▲33.1% | 163d ▼19.3% | 202d ▲19.5% | 169d ▲20.7% | 140d ▲12.9% | 124d |
| Working Capital Days | 142d ▲10.1% | 129d ▲5.7% | 122d ▲0.8% | 121d ▲16.3% | 104d ▲19.5% | 87d ▼10.3% | 97d ▲38.6% | 70d ▼9.1% | 77d ▲30.5% | 59d |
| ROCE | 20.0% ▼4.8% | 21.0% ▼4.5% | 22.0% ▼4.3% | 23.0% ▼39.5% | 38.0% ▲52.0% | 25.0% ▲38.9% | 18.0% ▲80.0% | 10.0% ▲150.0% | 4.0% ▼82.6% | 23.0% |
Source: Screener.in · Lower days = better efficiency